
CLAIMS

1. A hydrate of a compound represented by a structural formula:



(Ip^3);

or a pharmaceutically acceptable salt thereof, wherein:

G^1 is (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, halogen, cyano or nitro;

n is 0, 1 or 2;

G^{2a} is (C_1-C_4)alkyl, (C_1-C_2)haloalkyl, (C_3-C_4)cycloalkyl or (C_3-C_4)cycloalkyl(C_1-C_2)alkyl;

G^{2b} is hydrogen, methyl or ethyl;


R^1 is methyl or ethyl;

R^2 is phenyl or fluorophenyl; and

R^3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.


2. The hydrate of Claim 1, wherein n is 0.

3. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

4. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

5. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.


6. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


7. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

8. The hydrate of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

9. The hydrate of any one of Claims 1-8, wherein the compound is a monohydrate.

10. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the hydrate of any one of Claims 1-8.


11. The use of the hydrate of any one of Claims 1-8 for the manufacture of a medicament for the treatment of a disease associated with the activity or expression of 11β-HSD1.

12. The use of the hydrate of any one of Claims 1-8 for the manufacture of a medicament for the treatment of a human in need of inhibition of 11β-HSD1 activity.

13. The use of Claim 11, wherein the disease is diabetes.

14. The use of Claim 12, wherein the human is in need of treatment for diabetes.

15. A compound represented by the following structural formula:



;

wherein the compound is a monohydrate and crystalline.

16. The compound of Claim 15, wherein the compound crystallizes in the orthorhombic space group $P2_12_12_1$.

17. The compound of Claim 15, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 8.71, 12.93 and 19.16 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.


18. The compound of Claim 17, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 8.71, 12.93, 19.16, 19.45 and 21.06 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.

19. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound of Claim 15.

20. The use of the compound of Claim 15 for the manufacture of a medicament for treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemia, hyperlipidemia, insulin resistance, and dyslipidemia.

21. The use of Claim 20, wherein the disease is Type II diabetes mellitus.

22. A compound represented by the following structural formula:



;

wherein the compound is a monohydrate and crystalline.

23. The compound of Claim 22, wherein the compound crystallizes in the orthorhombic space group $P2_12_12_1$.

24. The compound of Claim 22, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 21.00, 21.72, and 23.98 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.

25. The compound of Claim 24, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 14.25, 21.00, 21.72, 23.10, 23.98, and 27.04 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.


26. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound of Claim 22.

27. The use of the compound of Claim 22 for the manufacture of a medicament for treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemia, hyperlipidemia, insulin resistance, and dyslipidemia.

28. The use of Claim 27, wherein the disease is Type II diabetes mellitus.

CLAIMS

1. A compound represented by the following structural formula:



;

wherein the compound is a monohydrate and crystalline, and wherein the compound crystallizes in the orthorhombic space group $P2_12_12_1$.

2. The compound of Claim 1, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 8.71, 12.93 and 19.16 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.


3. The compound of Claim 2, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 8.71, 12.93, 19.16, 19.45 and 21.06 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.

4. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound of Claim 1.

5. The use of the compound of Claim 1 for the manufacture of a medicament for treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemia, hyperlipidemia, insulin resistance, and dyslipidemia.

6. The use of Claim 5, wherein the disease is Type II diabetes mellitus.

7. A compound represented by the following structural formula:



wherein the compound is a monohydrate and crystalline, and wherein the compound crystallizes in the orthorhombic space group $P2_12_12_1$.

8. The compound of Claim 7, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 21.00, 21.72, and 23.98 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.

9. The compound of Claim 8, wherein the compound is characterized by X-ray powder diffraction peaks at 2θ angles 14.25, 21.00, 21.72, 23.10, 23.98, and 27.04 degrees (±0.05 degrees) using $CuK\alpha_1$ radiation.

10. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound of Claim 7.

11. The use of the compound of Claim 7 for the manufacture of a medicament for treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemia, hyperlipidemia, insulin resistance, and dyslipidemia.

12. The use of Claim 11, wherein the disease is Type II diabetes mellitus.